HER2-negative Clinical Trials in Shanghai, Shanghai Municipality
6 recruitingShanghai, Shanghai Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Phase 4
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
HER2-negative Breast CancerLeptomeningeal Metastasis
Fudan University37 enrolled1 locationNCT06230055
Recruiting
Phase 1
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Advanced Breast CancerAdvanced Prostate CancerTNBC+3 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.157 enrolled1 locationNCT06769425
Recruiting
Phase 2
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
HER2-negative Breast CancerBRCA-Mutated Breast Carcinoma
Fudan University130 enrolled1 locationNCT06516289
Recruiting
Not Applicable
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer
Breast Cancer FemaleHER2-negative Breast Cancer
Fudan University14 enrolled1 locationNCT06636591
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095